EN DE
Watch Definium Therapeutics, Inc. for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Definium Therapeutics, Inc. (DFTX) stock: price, quality, comparison

Price, quality, revenue and earnings and the peer comparison for Definium Therapeutics, Inc., from audited financials.

Price: $33.27. No valuation: the company's figures do not support a reliable fair value right now, so we deliberately show none.
Revenue growth (quarter YoY) 0.0% (industry 0.0%)
  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · ISIN CA24477V1058

DT Definium Therapeutics, Inc. logo Thin data Nov 6, 2026

Definium Therapeutics, Inc.

DFTX · US
Low debt
Insiders sold $5.6M (6M)
Quality 35/100
Negative free cash flow
Trails peers (2/7)
Narrow moat 14/100 · thin data
Downbeat coverage
Thin data
No fair value
Watch Definium Therapeutics, Inc. for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Which stocks are undervalued right now? Check free Discover now →

Company profile

Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders.

Show moreShow less

The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum disorder.

The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to Definium Therapeutics, Inc. in January 2026. Definium Therapeutics, Inc. is headquartered in New York, New York.

Quality Score breakdown

Overall quality 35/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 25
Are margins and returns getting better?
Cashflow 57
Do the profits arrive as real cash?
Financial strength 99
Debt, balance sheet and risk of trouble
Investment 0
Does it invest with discipline instead of growing at any price?
Low Volatility 0
How calm the share price moves, does not count
Price momentum 72
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 80
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, 5 officers or directors sold shares worth $5.6M and none bought.

  • SaleBrandi RobertsChief Financial Officer2× since Jun 25, 2026: 6,390 shares, avg. $40.56$259,172Sep 25, 202610b5-1 plan
  • SaleMark SullivanChief Legal Officer4× since Dec 26, 2025: 49,037 shares, avg. $29.48$1.4MSep 25, 202610b5-1 plan
  • SaleMatthew T. WileyChief Commercial Officer2× since Jun 25, 2026: 5,964 shares, avg. $40.64$242,358Sep 25, 202610b5-1 plan
  • SaleRobert BarrowChief Executive Officer, Director5× since Dec 26, 2025: 130,003 shares, avg. $30.62$4.0MSep 25, 202610b5-1 plan
  • SaleDaniel KarlinChief Medical Officer, Director4× since Dec 26, 2025: 34,506 shares, avg. $31.02$1.1MSep 25, 202610b5-1 plan

Plus 24 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 6, 2026. All filings at the SEC ↗

Revenue & earnings trend

What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch DFTX, get fair value alerts →

Earlier news

News mood ⓘNews mood, the average tone of recent news (53 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Very negative
Recent news coverage is unusually downbeat.

Compare Definium Therapeutics, Inc. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks

Beats the industry median on 2/6 measures
Overall it trails its industry peers.
Valuation
Quality Score 35 · Below median
Profitability
Return on assets −41.8% · Bottom 25%
Operating margin (12 months) 0.0% · Above median
Growth and dividend
Revenue growth (quarter YoY) 0.0% · Above median
Balance sheet
Debt / equity 0.12× · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 13.22× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)94 · sector 97
DIVIDEND (yield)0 · sector 22

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Incyte Corporation INCY $119.65 $199.23 +67% vs DFTX
Regeneron Pharmaceuticals, Inc REGN $904.35 $1,275 +41% vs DFTX
Genmab A/S GMAB kr 3,527 kr 3,999 +13% vs DFTX
WuXi Biologics (Cayman) Inc 2269 HK$47.62 HK$53.55 +12% vs DFTX
Samsung Biologics Co 207940 1,516,000 KRW 1,667,600 KRW +10% vs DFTX
Vertex Pharmaceuticals Incorporated VRTX $547.09 $596.75 +9% vs DFTX
argenx SE ARGX $927.21 $908.40 −2% vs DFTX
CSL Limited CSL A$202.04 A$183.04 −9% vs DFTX
Celltrion, Inc 068270 211,000 KRW 74,945 KRW −64% vs DFTX
Royalty Pharma plc RPRX $67.30 $19.01 −72% vs DFTX

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Evidence & backtest34 years, failed companies included Financial calculatorsDCF, Graham, PEG and more
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector

Frequently asked questions

What is the quality score of DFTX?
Definium Therapeutics, Inc. has a Quality Score of 35/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
How solid is the balance sheet of Definium Therapeutics, Inc. (DFTX)?
Balance-sheet figures for Definium Therapeutics, Inc. (as of Nov 6, 2026): return on equity −64.1%, debt of 0.12 per unit of equity. They feed the Quality Score of 35/100, which measures business quality independently of the share price.
Which stocks are comparable to Definium Therapeutics, Inc.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
What is the share price of Definium Therapeutics, Inc. (DFTX)?
The closing price on Nov 6, 2026 was $33.27. We carry closing prices from our data provider, not a live tick.

Key figures of Definium Therapeutics, Inc.

How large is the market capitalisation of Definium Therapeutics, Inc. (DFTX)?
The market capitalisation of Definium Therapeutics, Inc. is $4.4B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Definium Therapeutics, Inc. (DFTX)?
Earnings per share at Definium Therapeutics, Inc. are $−3.43. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Definium Therapeutics, Inc. (DFTX)?
The return on equity (ROE) of Definium Therapeutics, Inc. is −64.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Definium Therapeutics, Inc. (DFTX)?
On an EBIT basis the return on assets of Definium Therapeutics, Inc. is −48.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does Definium Therapeutics, Inc. (DFTX) generate?
The free cash flow of Definium Therapeutics, Inc. is −$132M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Definium Therapeutics, Inc. (DFTX) hold?
Definium Therapeutics, Inc. holds more cash than debt, $258M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Definium Therapeutics, Inc. in the live analysis

One click puts Definium Therapeutics, Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.